Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men
Status:
Completed
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this six-month treatment extension study is
- to assess feasibility of a lower starting dose of SOV2012-F1 (daily dose of 400 mg [200
mg with breakfast meal and 200mg with dinner meal]) to titrate individual doses in order
to further enhance drug administration.
- To examine the blood pressure (BP) effects of Marius's oral testosterone undecanoate
formulation, SOV2012-F1, using 24-hour ambulatory blood pressure monitoring (ABPM).